http://www.reportbuyer.com/rss.htmlResearch comprehensive market analysis on Country Pharmaceutical overviews in the Pharma & Healthcare industry. Reports include data on Europe, UK, USA, Asia and other global markets.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/asia_pacific_pharma_sector_analysis.htmlThe world continues to witness significant shift in the global pharmaceutical market landscape, with Asia-Pacific emerging as the fastest growing pharmaceutical market over the recent past. With low costs and favorable regulatory environment, the region has seen significant developments in the field of contract manufacturing, particularly in generics and APIs. Several technological advancements have also boosted the R&D activities in the region, helping the market to grow at double digit growth rate in recent years. c60c2d705f8f0d6b3e5347cce90b29ecWed, 11 Nov 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/united_kingdom_pharmaceuticals_healthcare_report_q4_2009.htmlIn BMI's Business Environment Ratings (BER) for Q409, the UK improved its position by one place, and is now ranked 5th of the 9 Western European markets surveyed. However, while the UK is one of the most developed pharmaceutical markets in the world, pressing economic and political issues ??. 44122884f1ce54a5fa8aff212249dd6eSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/estonia_pharmaceuticals_healthcare_report_q4_2009.htmlEstonia's pharmaceutical market is unlikely to be a prime target for multinational drugmakers expanding into foreign countries. Despite rapid economic growth in recent years, which has translated into strong headline growth for pharmaceutical expenditure, the country's population of just 1. 34mn means that total market size will remain among the lowest in Central and Eastern Europe (CEE). 7e66eb4902e0348beb3ea85129fa4540Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/snapshots_france_pharmaceuticals_2009.htmlSnapdata's Snapshots France Pharmaceuticals 2009 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the French pharmaceutical market and covers refundable, non-refundable and hospital use pharmaceuticals. Market value is based on consumption. 30793f093525066b9d53bad4f2793daeSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/czech_republic_pharmaceuticals_healthcare_report_q4_2009.htmlThe Czech Republic has one of the most developed and technologically advanced pharmaceutical markets in Central & Eastern Europe (CEE). Despite the impact of the economic downturn, BMI believes that Czech medicine sales growth will remain healthy, if not overly impressive, over the next five years, reflecting the country's status as one of the most mature in the region. In 2009, the drug sector is likely to contract in US dollar terms, reaching a value of US$3. cee0655b21142806d921a4a07fea32c7Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/united_states_pharmaceuticals_healthcare_report_q4_2009.htmlDespite a downturn in growth rates in the US pharmaceuticals & healthcare markets, the country remains a core component for any company looking to achieve global success. Healthcare spending in 2008 reached US$2. 3trn, while sales of pharmaceuticals topped US$309bn. 28562c2267b92bd3215eb97aafd547d1Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/russia_pharmaceuticals_healthcare_report_q4_2009.htmlThis quarter BMI introduces 10-year forecasts for the Russian pharmaceutical markets, providing an opportunity to look beyond the current financial crisis and assess the growth potential for the largest and most populous pharmaceutical market in Central and Eastern European (CEE). By 2018, we forecast that the Russian pharmaceutical market will be worth US$50. 9bn, representing an 11. 09928690519d4e06234388ea942d1657Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/china_healthcare_sector_analysis.htmlChina's healthcare industry is entering into a new era with advance development of the infrastructure system. The industry is blessed with several advantages like large population of the country, increasing ageing population, increasing prevalence of lifestyle disease and many more. The government has also boosted the industry growth by blessing the sector with a US$ 120 Billion reform package. 05c5713be097eaf4031d8ef54a68751cSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/india_pharmaceuticals_healthcare_report_q4_2009.htmlIn the Q409 update of BMI's India Pharmaceuticals & Healthcare report, we have introduced our 10-year Drug Expenditure Forecast Model. The country's US$14. 23bn pharmaceutical market is forecast to reach a value of US$44. 6a87d7e50642bd48092ecb30ae2a58c9Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/spain_pharmaceuticals_healthcare_report_q4_2009.htmlIn BMI's Business Environment Ratings for Q409, Spain remains placed fourth out of the nine Western European Markets surveyed. Spain's large and generously subsidised drug market, low generic penetration, ageing population and stable economic and political system mean that it scores highly compared with its regional neighbours. Relative weaknesses are slow population growth, bureaucratic processes, as well as low pharmaceutical prices that encourage parallel trade. e7dc7242f4d0720761ca1e979c4f8281Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/peru_pharmaceuticals_healthcare_report_q4_2009.htmlBMI calculates that pharmaceutical sales in Peru reached PEN2. 58bn (US$0. 88bn) in 2008. This represents impressive growth of 8. 4c19fb16ea2640b8424eb61c84714759Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/snapshots_australia_pharmaceuticals_2009.htmlSnapdata's Snapshots Australia Pharmaceuticals 2009 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Australian pharmaceutical market and covers Ethical and OTC drugs. Market value is based on sales. e2ee2db24f48dece9af0094b9a5f71dfSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/china_major_report_covers_impact_health_reforms_chinas_pharmaceutical_market.htmlMassive reforms are changing the world's fastest growing market By 2013, China's pharmaceutical market will nearly triple in size to become the third largest in the world with sales of $60 billion. Alongside rapid growth, however, the industry is facing major disruptions in the operating environment as the country implements a three year $124 billion health reform that represents just the first wave of systemic changes scheduled to take place over the next decade. Buyer characteristics, the product selection process, pricing, distribution channels, customer geographics and demographics - all of these will be profoundly different in the environment that is emerging under the new health reforms. 90973b488276c18715a5b272385ac742Sat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/snapshots_bulgaria_pharmaceuticals_2009.htmlSnapdata's Snapshots Bulgaria Pharmaceuticals 2009 provides 2007 year-end market size data, with 2008 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Bulgarian pharmaceutical market and covers prescription and OTC pharmaceuticals. Market value is based on factory prices. e56617f3382bb053a99b0bb517c25b8bSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/pharmaceutical_market_hungary.htmlHungary represents one of the more advanced pharmaceutical markets of Central Europe. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. In addition to the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. c1571cfe1d4e93fecd81394942efdc03Wed, 30 Sep 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/pharmaceutical_market_spain.htmlThe Spanish pharmaceutical market is the fifth largest in the EU-27. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. In addition to the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. 481f44d46883b16b9dd2edffda4c263dWed, 30 Sep 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/pharmaceutical_market_slovenia.htmlSlovenia has a sizeable domestic industry and is home to the two largest generics companies in Europe, Krka and Lek. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. In addition to the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year. 04e2191c8ea72d362943261672abf368Wed, 30 Sep 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/pharmaceutical_market_ireland.htmlWith a population of around 4. 3 million, the Republic of Ireland represents a small but advanced market for pharmaceuticals. The country has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. 706a790558327d1647d3dc08d561514bWed, 30 Sep 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/greece_pharmaceuticals_healthcare_report.htmlIt has been a mixed year so far for the Greek pharmaceutical market. Although the sector is outperforming all other domestic manufacturing sectors in 2009, according to data from the National Statistics Service of Greece, there are warning signs ahead. Over the first six months of 2009, both the production and retail indexes of basic pharmaceutical products and pharmaceutical preparations has continued to grow, while most other sectors have been contracting. 4c249314f71952b9b57b11e601f2454eWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/saudi_arabia_pharmaceuticals_healthcare_report_q4_2009.htmlIn BMI's updated Business Environment Rankings (BER), Saudi Arabia is ranked second, out of the 17 Middle East and African (MEA) markets surveyed. The country's score is propped up by its sizeable and wealthy population as well as a steady forecast annual growth of its drug expenditure. Over the forecast period, the Saudi pharmaceutical market is expected to post a compound annual growth rate (CAGR) of 5. 7a5ebe7fce8c70c04f273430ba833c73Wed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Country Reports (Pharmaceutical)